The multi-billion-dollar drug sector has endured a decade of under-performance. "Pfizer’s (PFE), Eli Lilly’s (LLY), Merck's (MRK), and Bristol Myers Squibb’s (BMY) stock is trading at half of their value 10 years ago and GlaxoSmithKline (GSK) is faring slightly better at a negative 25%," reports... Read more
The rising cost of development and research is making drug companies turn to each other for help. Rival companies that include Pfizer, AstraZeneca, and Roche plan on sharing clinical data in a standard format. But this isn't the first time we've seen pharmaceutical companies start to share data.